Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events

Pipeline & Publications

ProductIndicationDevelopment Phase
NT-300 Tablets (nitazoxanide) Influenza Phase 3
NT-300 Tablets + oseltamivir Influenza Phase 3
NT-300 Oral Powder (nitazoxanide) Influenza Phase 3
NT-300 Oral Powder (nitazoxanide) RSV Phase 2
RM-5061 Anti-infective Preclinical
RM-5038 Broad-spectrum antiviral Preclinical
RM-5064 Broad-spectrum antiviral Preclinical

Peer-reviewed publications on investigational products
DISCLAIMER: This information concerns a use that has not been approved or cleared by the FDA.

Publications

The publications listed on this website are provided as a resource only to illustrate the nature and breadth of our research in the field of infectious diseases. The listed publications may reference the study of drugs that are investigational in the US, meaning that they have not been approved or determined to be safe and effective by the FDA and are not commercially available.

Helminths

  • Rossignol, J.F. & Maisonneuve, H. Nitazoxanide in the Treatment of Taenia saginata and Hymenolepis nana. American Journal of Tropical Medicine & Hygiene. 1984; 33: 511-512.
  • Jave-Ortiz, J, Chegne, NL, Gargala, G, Favennec, L. Comparative clinical study of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis snd hymenolepiasis. Transactions of the Royal Society of Tropical Medicine & Hygiene. 2002:96:1-4.
  • Favennec, L., Jave Ortiz, J., Gargala, G., Lopez Chegne, N., Ayoub, A & Rossignol, J.F. Double Blind Randomized Placebo Controlled Study of nitazoxanide in the Treatment of Fascioliasis in Adults and Children from Northern Peru. Alimentary Pharmacology & Therapeutics, 2003; 17: 265-270.

Protozoa

  • Rossignol, J.F., Ayoub, A. & Ayers, M.S. Treatment of Diarrhea Caused by Cryptosporidium parvum: a Propective Randomized Double-Blind Placebo-Controlled Study of Nitazoxanide. Journal of Infectious Diseases. 2001; 184:103-106.
  • Rossignol, J.F. , Kabil, S.M., Younis, A. M. & El-Gohary, Y., Double-blind Placebo Controlled Study of Nitazoxanide in the Treatment of Cryptosporidial Diarrhea in 90 Immunocompetent Adults and Adolescents from the Nile Delta of Egypt. Clinical Gastroenterology & Hepatology. 2006; 4: 320-324.
  • Rossignol, J.F., Hidalgo, H., Feregrino, M., Higuera, F., Gomez, W.H., Romero, J.L., Padierna, J., Geyne, A., Ayers, M.S. A Double Blind Placebo Controlled Study of Nitazoxanide in the Treatment of Cryptosporidial Diarrhea in AIDS Patients. Transactions of the Royal Society of Tropical Medicine & Hygiene. 1998; 92: 663-666.
  • Amadi, B, Mwiya, M, Musuku, J, Watuka, A, Sianongo, S, Ayoub, A & Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet. 2002;360:1375-1380.  
  • Rossignol, J.F. Nitazoxanide in the Treatment of Acquired Immune Deficiency Syndrome-Related Cryptosporidiosis: Results of the United States Compassionate use Program in 365 patients. Alimentary Pharmacology & Therapeutics. 2006; 24: 887-894. (ISI CI: 35)
  • Ortiz, JJ, Ayoub, A, Gargala, G, Chegne, NL & Favennec, L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Alimentary Pharmacology & Therapeutics. 2001;15:1409-1415.
  • Rossignol, J.F., Ayoub, A. & Ayers, M.S. Treatment of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica/dispar: a Double Blind Placebo Controlled Study of Nitazoxanide. Journal of Infectious Diseases. 2001;184:381-384.
  • Rossignol, J.F., Kabil, S.M., El-Gohary, Y. & Younis, A.M. Nitazoxanide in the Treatment of Amebiasis. Transactions of the Royal Society of Tropical Medicine & Hygiene. 2007;101:1025-1031.
  • Rossignol, J.F., Kabil, S.M., Said, M., Samir, H., Younis, A. Effect of Nitazoxanide in Persistent Diarrhea and Enteritis Associated with Blastocystis hominis. Clinical Gastroenterology & Hepatology. 2005;3:987-991.

Viruses

  • Rossignol, J.F., Abou Zekry, M., Abeer Hussein & Santoro, M.G. Effect of Nitazoxanide in Treating Severe Rotavirus Diarrhea: a Randomized, Double-Blind, Placebo-Controlled Trial. Lancet. 2006; 368: 124-129.
  • Rossignol, J.F. & El-Gohary, Y. M. Nitazoxanide in the Treatment of Viral Gastroenteritis: a Randomized Double Blind Placebo Controlled Trial. Alimentary Pharmacology & Therapeutics. 2006:24:1423-1430.
  • Rossignol, J.F., Elfert, A., El-Gohary, Y. & Keefe, E.B. Improved Virologic Response in Chronic Hepatitis C Genotype 4. Patients Given Nitazoxanide, Peginterferon, and Ribavirin. Gastroenterology 2009; 136:856-862.
  • Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., Bardin, M., Rossignol, J.F. A Randomized, Double-Blind, Placebo Controlled Clinical Trial of Nitazoxanide in Adults and Adolescents with Acute Uncomplicated Influenza. Lancet Infectious Diseases. 2014;14:609-618.

Bacteria

  • Dubreuil, L, Houcke, I, Mouton, Y & Rossignol, JF. In vitro Evaluation of Activities of Nitazoxanide and Tizoxanide against Anaerobes and Aerobic Organisms. Antimicrobial Agents and Chemotherapy. 1996; 40: 2266-2270.
  • Pankuch, GA & Appelbaum, PC. Activity of tizoxanide and nitazoxanide compared to five other thiazolides and three other agents against anaerobic species. Antimicrobial Agents & Chemotherapy. 2006;50: 1112-1117
  • Finegold, SM, Molitoris, D, Väisänen, M-L. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrobial Agents and Chemotherapy. 2009; 53: 281-286.
  • Mégraud. F, Occhialini, A & Rossignol, JF. Nitazoxanide, a Potential Drug to Eradicate Helicobacter pylori with no Cross Resistance to Metronidazole. Antimicrobial Agents & Chemotherapy. 1998; 42: 2836-2840.
  • McVay CS & Rolfe, RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrobial Agents & Chemotherapy. 2000;44:2244-2258
  • Hecht, DW, Galang, MA, Sambol, SP, Osmolski, JR, Johnson, S, Gerding, DN. In Vitro Activity of Fifteen Antimicrobial Agents Against 110 Toxigenic Clostridium difficile Clinical Isolates Collected from 1983-2004. Antimicrobial Agents & Chemotherapy. 2007;51:2716-19
  • Freeman, J, Baines, SD, Todhunter, SL Huscroft, GS & Wilcox, MH. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. Journal of Antimicrobial Chemotherapy. 2011;66: 1407-1408.
  • Musher, DM, Logan, N., Hamill, RJ, DuPont, HL, Lentnek, A, Gupta, A & Rossignol, JF., Nitazoxanide in the Treatment of Clostridium difficile Associated Diseases. Clinical Infectious Diseases. 2006; 43:421-427.
  • Musher, DM, Logan, N, Bressler, AM, Johnson, DP & Rossignol, JF. Nitazoxanide Versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study. Clinical Infectious Diseases, 2009:48:e41-46.